Dosing and uses of Panretin (alitretinoin topical)
Adult dosage forms and strengths
geL
- 0.1%
AIDS-Related Kaposi's Sarcoma
Initially apply BID to lesions; may increase to TID-QId
Pediatric dosage forms and strengths
Safety & efficacy not established
Panretin (alitretinoin topical) adverse (side) effects
>10%
Rash (77%)
Pain (34%)
Pruritus (11%)
1-10%
Exfoliative dermatitis (9%)
Edema (8%)
Skin changes (8%)
Paresthesia (3%)
Warnings
Contraindications
Hypersensitivity to retinoids
Concomitant systemic Kaposi's sarcoma Tx
Cautions
Avoid pregnancy
Pregnancy and lactation
Pregnancy category: d
Lactation: excretion in milk unknown/not recommended
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Panretin (alitretinoin topical)
Onset: 2-14 wk
Absorption: negligible
Metabolism: in vitro data unlikely relevant since little absorption
Excretion: N/A
Mechanism of action
Endogenous retinoid, regulates genes that control cellular differentiation
